US equities |
MU $1,035.84 ▼-4.79% NVDA $230.48 ▼-2.94% SNDK $1,609.46 ▼-4.90% AMD $620.68 ▼-3.90% INTC $107.08 ▼-5.34% AAPL $340.42 ▲+1.11% META $720.89 ▼-0.06% SPCX $160.57 ▼-4.19%
FinancialContent

CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

5.350 -0.080 (-1.47%)
Delayed Quote Updated: 12:56 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CNS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
24 25 Next >
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
We're starting off trading on Tuesday with a look into the biggest pre-market stock movers traders need to keep an eye on today! 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors
Via ACCESSWIRE
News headline image
CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin
Via ACCESSWIRE
Novel Brain Scan Technique Exposes Vulnerability of Gliomas
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Names Seasoned Biotech Leader to Board of Directors
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reaches Planned Enrollment Berubicin Study for the Treatment of GBM
Via Investor Brand Network
News headline image
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
Multidisciplinary Consortium Sets Sights on Developing AI to Detect Gliomas
Via Investor Brand Network
Topics Artificial Intelligence
Light, Viruses Could Transform Brain-Tumor Treatment
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces DSMB Recommendation to Continue Pivotal GBM Study without Modification
Via Investor Brand Network
Researchers Discuss How Brain Cancer Radiotherapy Side Effects Can Be Reduced
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Interim Analysis on Global Berubicin Trial Showing Promising Results
Via Investor Brand Network
Topics Death
News headline image
How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure
Via ACCESSWIRE
News headline image
How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure ↗
Every form of cancer is devastating, but the unfortunate reality is not all cancers are created equal. There are certain forms that are more deadly, with Glioblastoma (GBM) being one of the worst. GBM... 
Via Benzinga
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Presents Updated Safety Data from Berubicin Study at SNO Annual Gathering
Via Investor Brand Network
News headline image
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
Via ACCESSWIRE
Study Finds DNA Loops in Brain Tumors in Kids Amplify Relapse Risk
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Release Interim Data by Year End for Lead Treatment Candidate Berubicin
Via Investor Brand Network
Topics Death
News headline image
CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate
Via ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q3 2023 Financial Results, Update on Berubicin Study
Via Investor Brand Network
News headline image
CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate ↗
Glioblastoma is a highly aggressive type of brain cancer with no cure, leading to a grim prognosis and average survival time of only 14 to 16 months. With no approved treatment for recurrent GBM... 
Via Benzinga
News headline image
CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End
Via ACCESSWIRE
Brain Cancer Reemergence Could Soon Be Detected Using a Finger-Prick Test
Via Investor Brand Network
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
24 25 Next >